Phase 2RecruitingPriority 3 · Moderate priorityNCT06519526
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Plain-language summary
This trial is testing the combination of SHR-0302 (JAK inhibitor) and SHR-2554 (EZH2 inhibitor) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
SHR-0302 (DRUG): SHR-0302 will be administered orally as tablets. | SHR-2554 (DRUG): SHR-2554 will be administered orally as tablets.
SHR-0302, SHR-2554
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details